Lineage Cell Therapeutics Inc (LCTX) concluded trading on Thursday at a closing price of $1.15, with 3.7 million shares of worth about $4.25 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 70.37% during that period and on July 24, 2025 the price saw a gain of about 6.48%. Currently the company’s common shares owned by public are about 228.36M shares, out of which, 227.36M shares are available for trading.
Stock saw a price change of 16.16% in past 5 days and over the past one month there was a price change of 6.48%. Year-to-date (YTD), LCTX shares are showing a performance of 12.75% which increased to 128.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.37 but also hit the highest price of $1.15 during that period. The average intraday trading volume for Lineage Cell Therapeutics Inc shares is 2.26 million. The stock is currently trading 15.32% above its 20-day simple moving average (SMA20), while that difference is up 40.25% for SMA50 and it goes to 72.44% higher than SMA200.
Lineage Cell Therapeutics Inc (AMEX: LCTX) currently have 228.36M outstanding shares and institutions hold larger chunk of about 44.78% of that.
The stock has a current market capitalization of $262.60M and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$0.08 in the same period. It has Quick Ratio of 3.82 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LCTX, volatility over the week remained 9.58% while standing at 10.27% over the month.
Stock’s fiscal year EPS is expected to drop by -9.73% while it is estimated to increase by 49.86% in next year. EPS is likely to grow at an annualized rate of 9.01% for next 5-years, compared to annual growth of -2.93% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on August 20, 2024 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by Robert W. Baird stated Lineage Cell Therapeutics Inc (LCTX) stock as an Outperform in their note to investors on November 02, 2022, suggesting a price target of $5 for the stock. On June 14, 2022, B. Riley Securities Initiated their recommendations, while on August 19, 2021, Noble Capital Markets Initiated their ratings for the stock with a price target of $8. Stock get an Overweight rating from Cantor Fitzgerald on March 31, 2021.
